These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 2411125

  • 1. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
    Satake K, Kanazawa G, Kho I, Chung Y, Umeyama K.
    Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
    [Abstract] [Full Text] [Related]

  • 2. [Assay of serum elastase 1 in adenocarcinoma of the pancreas: diagnostic value, compared and combined study with serum CEA and CA 19-9].
    Charneau J, Douay O, Daver A, Boyer J.
    Gastroenterol Clin Biol; 1988 Aug; 12(6-7):548-52. PubMed ID: 3166429
    [Abstract] [Full Text] [Related]

  • 3. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K, Tasaki N, Miyagawa H, Yoshikawa T, Kondo M.
    Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
    [Abstract] [Full Text] [Related]

  • 4. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 Feb; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 5. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
    Del Favero G, Fabris C, Panucci A, Basso D, Plebani M, Baccaglini U, Leandro G, Burlina A, Naccarato R.
    Bull Cancer; 1986 Feb; 73(3):251-5. PubMed ID: 3530354
    [Abstract] [Full Text] [Related]

  • 6. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R, Billi P, Plate L, Laudadio MA, Sprovieri G.
    Ital J Gastroenterol; 1995 Feb; 27(6):296-9. PubMed ID: 8562994
    [Abstract] [Full Text] [Related]

  • 7. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
    Schmiegel WH, Eberl W, Kreiker C, Kalthoff H, Bützow GH, Jessen K, Klapdor R, Soehendra N, Wargenau M, Classen M.
    Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
    [Abstract] [Full Text] [Related]

  • 8. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K, Chung YS, Umeyama K, Takeuchi T, Kim YS.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Serum pancreatic enzymes and enzyme inhibitor as a tumor marker for pancreatic cancer].
    Ogawa M.
    Rinsho Byori; 1986 Nov; 34(11):1229-35. PubMed ID: 2434691
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
    Piantino P, Andriulli A, Gindro T, Pecchio F, Masoero G, Cavallini G, Naccarato R, Dobrilla G.
    Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359
    [Abstract] [Full Text] [Related]

  • 13. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
    Lucarotti ME, Habib NA, Kelly SB, Rothnie ND, Nelson O, Lindholm L, Cooper MJ, Wood CB, Williamson RC.
    Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
    [Abstract] [Full Text] [Related]

  • 14. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
    Safi F, Büchler M, Schenkluhn B, Beger HG.
    Dtsch Med Wochenschr; 1984 Dec 07; 109(49):1869-73. PubMed ID: 6209082
    [Abstract] [Full Text] [Related]

  • 15. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon].
    Klapdor R, Klapdor U, Bahlo M, Dallek M, Kremer B, van Ackeren H, Schreiber HW, Greten H.
    Dtsch Med Wochenschr; 1984 Dec 21; 109(51-52):1949-54. PubMed ID: 6595110
    [Abstract] [Full Text] [Related]

  • 16. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I.
    Anticancer Res; 1993 Dec 21; 13(5C):1883-7. PubMed ID: 8267397
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
    Czakó L, Takács T, Babarczy E, Dux L, Lonovics J.
    Orv Hetil; 1997 Nov 23; 138(47):2981-5. PubMed ID: 9432648
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Tumor markers of pancreatic cancer].
    Takami H, Hishinuma S, Shintoku J, Furuuchi T, Ogata Y, Abe O.
    Gan To Kagaku Ryoho; 1985 Feb 23; 12(2):212-9. PubMed ID: 3855615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.